幹細胞治療の世界市場

幹細胞治療の世界市場は2030年までに11億米ドルに達する見込み

2023年に3億7,930万米ドルと推定された幹細胞治療の世界市場は、2030年には11億米ドルに達し、分析期間2023-2030年のCAGRは16.4％で成長すると予測されます。本レポートで分析したセグメントの1つである同種幹細胞治療は、CAGR 16.7％を記録し、分析期間終了までに10億米ドルに達すると予測されています。自家幹細胞治療セグメントの成長率は、分析期間中CAGR 10.0％と推定されます。

米国市場は1億440万米ドルと推定、中国はCAGR 15.5％で成長すると予測

米国の幹細胞治療市場は、2023年に1億440万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億6,560万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは15.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.3%と13.8%と予測されています。欧州では、ドイツがCAGR 11.5%で成長すると予測されています。

世界の幹細胞治療市場- 主要動向と促進要因のまとめ

幹細胞治療はどのように患者ケアに革命をもたらすのか？

幹細胞治療は、幹細胞を用いて損傷した組織を再生し、病気を治療し、患者の機能を回復させる。血液疾患、自己免疫疾患、整形外科的損傷、神経変性疾患など、幅広い疾患に使用されています。幹細胞はその再生能力により、対症療法にとどまらない治癒的治療の可能性を提供し、現代ヘルスケアに不可欠なものとなっています。治療には、疾患や治療法に応じて、自家（患者由来）幹細胞や同種（ドナー由来）幹細胞が用いられます。医療科学が再生医療や個別化治療に注目する中、幹細胞治療は急性および慢性疾患の両方に対する有望なソリューションとして浮上しています。

幹細胞治療市場の主要セグメントは？

主な種類には同種幹細胞療法と自家幹細胞療法があり、同種幹細胞療法は血液悪性腫瘍、免疫疾患、遺伝性疾患などの治療に幅広く使用されているため、大きな市場シェアを占めています。用途としては、整形外科、神経内科、循環器内科、血液内科、自己免疫疾患などがあり、中でも血液内科は、白血病やリンパ腫、その他の血液疾患の治療における幹細胞移植の有効性に牽引された主要分野です。エンドユーザーには、病院、研究機関、専門クリニックが含まれ、病院は入院治療と外来治療の両方で最先端の幹細胞治療を提供しているため、市場をリードしています。

幹細胞治療はどのようにヘルスケアに統合されているのか？

整形外科では、幹細胞治療は関節損傷、軟骨損傷、腱修復の治療に使用され、組織再生を促進し、痛みを軽減し、運動能力を向上させます。神経学では、幹細胞はパーキンソン病、脊髄損傷、脳卒中回復などの疾患に対して、損傷した神経細胞の代わりとなり、神経修復をサポートすることで、治療の可能性を提供します。心臓病学では、幹細胞治療は心臓発作後の心臓組織再生をターゲットとし、心臓機能の改善と合併症の軽減を目指しています。さらに、多発性硬化症や全身性エリテマトーデスのような自己免疫疾患は、免疫系をリセットし長期的な寛解をもたらす幹細胞移植によって治療されます。

幹細胞治療市場の成長を促進する要因は？

幹細胞治療市場の成長は、神経変性疾患、心不全、免疫疾患など、治療法が限られている疾患に対する再生治療への需要の高まりなど、いくつかの要因によって牽引されています。幹細胞研究、臨床プロトコール、送達方法の進歩により、これらの治療法の安全性、有効性、利用しやすさが改善され、医療分野での幅広い採用が後押しされています。幹細胞治療により、患者固有の病態や遺伝子プロファイルに基づいた個別化治療が可能になるため、個別化医療やオーダーメイド治療が注目され、需要がさらに高まっています。さらに、規制当局の認可の拡大、臨床試験の成功率の上昇、バイオテクノロジーや再生医療への投資の増加などが市場開拓に寄与し、幹細胞治療の開発と商業化が加速しています。

セグメント

種類（同種移植、自家移植）;細胞源（脂肪組織由来MSC、骨髄由来MSC、胎盤/臍帯由来MSC、その他の細胞源）;用途（筋骨格系疾患、創傷・傷害、心血管系疾患、消化器系疾患、その他の用途）

調査対象企業の例（注目の12社）

• Advanced Cell Technology
• Anterogen, Ltd.
• Biotime, Osiris Therapeutics
• Cynata
• Cytori Therapeutics
• HolostemTerapieAvanzateS.r.l.
• Human Longevity
• JCR Pharmaceuticals
• Medipost
• Mesoblastand AlloSource
• NuVasive
• Osiris Therapeutics, Inc.
• Pharmicell
• Promethera Biosciences
• RTI Surgical
• Stemcell Technologies

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Stem Cell Therapy Market to Reach US$1.1 Billion by 2030

The global market for Stem Cell Therapy estimated at US$379.3 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 16.4% over the analysis period 2023-2030. Allogeneic Stem Cell Therapy, one of the segments analyzed in the report, is expected to record a 16.7% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Autologous Stem Cell Therapy segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$104.4 Million While China is Forecast to Grow at 15.5% CAGR

The Stem Cell Therapy market in the U.S. is estimated at US$104.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$165.6 Million by the year 2030 trailing a CAGR of 15.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.3% and 13.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.5% CAGR.

Global Stem Cell Therapy Market - Key Trends and Drivers Summarized

How Is Stem Cell Therapy Revolutionizing Patient Care?

Stem cell therapy involves the use of stem cells to regenerate damaged tissues, treat diseases, and restore function in patients. It is used for a wide range of conditions, including hematological disorders, autoimmune diseases, orthopedic injuries, and neurodegenerative diseases. Stem cells, due to their regenerative capabilities, offer the potential for curative treatments that go beyond symptomatic relief, making them an integral part of modern healthcare. The therapy can involve autologous (patient-derived) or allogeneic (donor-derived) stem cells, depending on the condition and the treatment approach. As medical science focuses on regenerative and personalized treatments, stem cell therapy has emerged as a promising solution for both acute and chronic conditions.

What Are the Key Segments in the Stem Cell Therapy Market?

Key types include allogeneic and autologous stem cell therapies, with allogeneic therapies holding a significant market share due to their broader use in treating conditions like hematological malignancies, immune disorders, and inherited diseases. Applications cover orthopedics, neurology, cardiology, hematology, and autoimmune diseases, with hematology representing a major segment driven by the effectiveness of stem cell transplants in treating leukemia, lymphoma, and other blood disorders. End-users include hospitals, research institutes, and specialty clinics, with hospitals leading the market as they provide advanced stem cell therapies for both inpatient and outpatient care.

How Is Stem Cell Therapy Integrated Across Healthcare?

In orthopedics, stem cell therapy is used to treat joint injuries, cartilage damage, and tendon repair by promoting tissue regeneration, reducing pain, and improving mobility. In neurology, stem cells offer potential treatments for conditions like Parkinson’s disease, spinal cord injuries, and stroke recovery by replacing damaged neurons and supporting neural repair. In cardiology, stem cell therapy targets heart tissue regeneration following heart attacks, aiming to improve cardiac function and reduce complications. Additionally, autoimmune diseases like multiple sclerosis and systemic lupus erythematosus are treated with stem cell transplants that reset the immune system and provide long-term remission.

What Factors Are Driving the Growth in the Stem Cell Therapy Market?

The growth in the Stem Cell Therapy market is driven by several factors, including increasing demand for regenerative treatments that address conditions with limited curative options, such as neurodegenerative diseases, heart failure, and immune disorders. Advancements in stem cell research, clinical protocols, and delivery methods have improved the safety, efficacy, and accessibility of these therapies, supporting wider adoption across medical fields. The focus on personalized medicine and tailored treatments has further fueled demand, as stem cell therapy enables individualized care based on patient-specific conditions and genetic profiles. Additionally, growing regulatory approvals, increased clinical trial success rates, and rising investments in biotechnology and regenerative medicine have contributed to market growth, accelerating the development and commercialization of stem cell therapies.

SCOPE OF STUDY:

The report analyzes the Stem Cell Therapy market in terms of US$ by the following Application; Cell Source; Type, and Geographic Regions/Countries:

Segments:

Type (Allogeneic, Autologous); Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs, Other Cell Sources); Application (Musculoskeletal Disorders, Wounds & Injuries, Cardiovascular Diseases, Gastrointestinal Diseases, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 12 Featured) -

• Advanced Cell Technology
• Anterogen, Ltd.
• Biotime, Osiris Therapeutics
• Cynata
• Cytori Therapeutics
• HolostemTerapieAvanzateS.r.l.
• Human Longevity
• JCR Pharmaceuticals
• Medipost
• Mesoblastand AlloSource
• NuVasive
• Osiris Therapeutics, Inc.
• Pharmicell
• Promethera Biosciences
• RTI Surgical
• Stemcell Technologies

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Stem Cell Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Diseases Drives Demand for Stem Cell Therapy
  • Increasing Focus on Regenerative Medicine Spurs Growth in Stem Cell Therapy
  • Advancements in Cell-Based Immunotherapies Propel Market Expansion
  • Rising Adoption in Neurological Disorders Expands Addressable Market
  • Growing Use in Hematological Disorders Strengthens Business Case
  • Expansion of Cardiovascular Applications Spurs Demand for Stem Cell Therapy
  • Emergence of Off-the-Shelf Allogeneic Therapies Enhances Adoption
  • Growing Focus on Rare Disease Treatment Expands Market Potential
  • Rising Approvals for Clinical Trials Accelerates Demand for Stem Cell Therapy
  • Advancements in Gene-Edited Stem Cells Propel Therapeutic Opportunities
  • Rising Focus on Age-Related Degenerative Conditions Fuels Demand
  • Growing Interest in Autologous Therapies Expands Adoption
  • Emergence of Combination Therapies Strengthens Stem Cell Market
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 27: World 16-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 30: World 16-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 33: World 16-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 34: World Stem Cell Therapy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Placental / Umbilical Cord-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Placental / Umbilical Cord-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Placental / Umbilical Cord-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• JAPAN
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• CHINA
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 73: China 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• EUROPE
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• FRANCE
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 94: France 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• GERMANY
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Rest of Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 124: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Asia-Pacific Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 133: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Asia-Pacific Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 136: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 139: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of World Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of World 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of World Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of World 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Rest of World Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 148: Rest of World 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030

IV. COMPETITION